Mark is a corporate lawyer and has more than thirty years’ experience in leveraging intellectual property for licensing and royalties. He has also been responsible for building up a succession of businesses in Europe and the US in the biopharma field. Presently he is Company Secretary at UCB, a global biopharma company with activities in forty countries and turnover in 2018 of €4.62 billion.

Mark serves as Chairman of the Board and supervises all corporate governance for the Company. As a leading expert in international patent law, he advises the Company on its intellectual property strategy.

As a result of his extensive City of London and international business contacts, Mark has been able to introduce the Company team to business leaders in relevant sectors, including senior board level ‘C-suite’ members in companies such as BP and Shell as well as government ministers.